Trial Outcomes & Findings for Memantine in Adult Autism Spectrum Disorder (NCT NCT01078844)
NCT ID: NCT01078844
Last Updated: 2017-07-26
Results Overview
TERMINATED
NA
4 participants
12 weeks
2017-07-26
Participant Flow
4 participants were enrolled in this study. It was terminated prematurely and the P.I. was never un-blinded. In an attempt to enter the information which was obtained within the confines of the system, all enrollment information and baseline characteristics have been entered into the experimental arm.
Participant milestones
| Measure |
All Participants
Treatment as usual plus memantine
memantine: memantine 5-20 mg daily
OR
Treatment as usual plus Placebo
|
|---|---|
|
Overall Study
STARTED
|
4
|
|
Overall Study
COMPLETED
|
0
|
|
Overall Study
NOT COMPLETED
|
4
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Memantine in Adult Autism Spectrum Disorder
Baseline characteristics by cohort
| Measure |
All Participants
n=4 Participants
Treatment as usual plus memantine
memantine: memantine 5-20 mg daily
OR
Treatment as usual plus Placebo
|
|---|---|
|
Age, Customized
Age, years (18-85
|
4 Participants
n=5 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
2 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
4 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: 12 weeksPopulation: This study was terminated prematurely and data was not collected for this outcome measure.
Outcome measures
Outcome data not reported
Adverse Events
All Participants
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Eric Samstad, MD
Johns Hopkins University School of Medicine
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place